Kato, Hideaki
,
Fujita, Hiroyuki http://orcid.org/0000-0002-6084-6863
Akiyama, Nobu
Kimura, Shun-ichi
Hiramoto, Nobuhiro
Hosono, Naoko
Takahashi, Tsutomu
Shigeno, Kazuyuki
Minamiguchi, Hitoshi
Miyatake, Junichi
Handa, Hiroshi
Kanda, Yoshinobu
Yoshida, Minoru
Miyawaki, Shuichi
Ohtake, Shigeki
Naoe, Tomoki
Kiyoi, Hitoshi
Matsumura, Itaru
Miyazaki, Yasushi
Article History
Received: 28 December 2017
Accepted: 23 May 2018
First Online: 2 June 2018
Compliance with ethical standards
:
: Hideaki Kato received grants from Japan Blood Products Organization and Shionogi. Hiroyuki Fujita received honoraria from Novartis, and payment for manuscripts from Chugai Pharmaceutical. Shun-ichi Kimura received honoraria from Pfizer, Astellas, Sumitomo Dainippon Pharma, and Nippon Kayaku. Tsutomu Takahashi received grants from Chugai Pharmaceutical, Kyowa Hakko Kirin, and Astellas, honoraria from Chugai Pharmaceutical, Kyowa Hakko Kirin, Taiho Pharmaceutical and Celgene Corporation. Junichi Miyatake received honoraria from Kyowa Hakko Kirin, Celgene Corporation, Sumitomo Dainippon Pharma, Takeda Pharmaceutical, and Chugai Pharmaceutical. Hiroshi Handa received consulting fee from Takeda Pharmaceutical and Celgene Corporation, grants and honoraria from Celgene Corporation, Takeda Pharmaceutical, Pfizer, Astellas, Sanofi, MSD, Shionogi, Daiichi Sankyo, Kyowa Hakko Kirin, Novartis, and Shire. Shunichi Miyawaki received a consulting fee from Astellas and expert testimony from Ohtsuka Pharmaceutical and Novartis. Hitoshi Kiyoi received consulting fees from Astellas and Daiichi Sankyo, grants from Chugai Pharmaceutical, Bristol-Myers Squibb, Kyowa Hakko Kirin, Zenyaku Kogyo, FUJIFILM Corporation, Nippon Boehringer Ingelheim, Astellas and Celgene Corporation, and honoraria from Bristol-Myers Squibb and Pfizer. Other authors: none to declare.